ArticleFrontiers in cardiovascular medicine2023
Case report: Treatment of left-sided valve endocarditis using the Transapical AngioVac System and cerebral embolism protection device: A case series.
Article in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Introducing the use of AngioVac in nonbacterial thrombotic endocarditis: a systematic review.Future cardiology · 2025Pooled it
- Percutaneous Mechanical Aspiration of Left-Sided Intracardiac Masses for Prohibitive Surgical Candidates: A Single-Center Experience.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Percutaneous Vacuum-Assisted Debulking of Infected and Non-Infected Left-Sided Cardiac Masses Using the AngioVac System: A Systematic Review of Published Case Reports and Case Series.Journal of clinical medicine · 2026Review
- Recurrence of Prosthetic Aortic Valve Endocarditis After Percutaneous Mechanical Aspiration.JACC. Case reports · 2026Article
- Percutaneous Debulking of Bioprosthetic Mitral Valve Vegetations: Preserving Valve Function in Recurrent Infective Endocarditis.JACC. Case reports · 2026Article
- Vacuum-assisted thrombectomy for intracardiac and intravascular thrombi: A single-center experience.JTCVS structural and endovascular · 2025Article
- Vacuum-Assisted Aspiration of Intracardiac Masses as a Bridge or Alternative to Surgery.JACC. Case reports · 2025Article
- Transcatheter Vacuum-Assisted Mass Extraction on a Mitral Bioprosthesis.JACC. Case reports · 2025Article
- Minimally invasive aspiration of thrombi and masses in left-sided cardiac chambers: a comprehensive literature review.Frontiers in cardiovascular medicine · 2025Review
- Aspiration of Left Atrial Masses Using the Large-Bore Manual Aspiration System: The ASPIRATE LA Procedure.JACC. Case reports · 2024Article
- Percutaneous Mechanical Aspiration for Infective Endocarditis: Proceedings From an Inaugural Multidisciplinary Summit and Comprehensive Review.Journal of the Society for Cardiovascular Angiography & Interventions · 2024Review
- Transcatheter vacuum-assisted aspiration of large intracardiac and intravascular masses.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2024Review
- Thromboaspiration of a left-sided bioprosthetic valve thrombosis by a mini-access: the Lausanne novel procedure.Frontiers in cardiovascular medicine · 2024Article
- Prevalence of Right- and Left-Sided Endocarditis Among Intravenous Drug Use Patients at a Large Academic Medical Center.Cardiology research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The AngioVac System (AngioDynamics, Latham, NY) was developed for the treatment of right-sided heart and intravenous masses. Lately, it has been employed to deal with left-sided heart masses, in particular, native valve endocarditis (NVE) and valve prostheses endocarditis (VPE) in high-risk patients. Left-sided heart endocarditis has a high morbidity, and it also has a high mortality when open heart surgery is performed. Recently, patients presenting with left NVE and VPE have been treated with the off-label use of the AngioVac System even if the solution presents a considerable cerebral embolization risk issue due to the risk of fragmentation rather than a complete en-bloc aspiration of the masses. A percutaneous cerebral embolism protection system is currently used in TAVI procedures, especially when the native valve presents extensive calcifications and consequent significant embolic risks. We hereby present a clinical case series of a combined utilization of the AngioVac System and cerebral embolism protection system Triguard (Keystone Heart Ltd., Herzliya, Israel) to treat left NVE and VPE in prohibitive-surgical-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.